Workshop participants discussed: the role of HIV subtypes in disease; the treatment of oral candidiasis; the relationship between and among viral load, CD4+ counts, oral candidiasis and oral hairy leukoplakia, pigmentation; and the development of a reliable oral index to predict disease progression. Regarding HIV, the literature revealed that Type I (HIV-I), in particular group M, is involved in the majority (90%) of documented infections, and groups N and O to a lesser extent. Viral envelope diversity led to the subclassification of the virus into nine subtypes, or clades—A–D, F-H, J, and K—each dominating in different geographical areas. HIV-2, currently occurring mostly in West Africa, appears to be less virulent. No evidence could be produced of any direct impact of type, subtype, or clade on oral lesions, and participants believed that further research is not feasible. Oral candidiasis in patients from resource-poor countries should be prevented. When the condition does occur, it should be treated until all clinical symptoms disappear. Oral rinsing with an antimicrobial agent was suggested to prevent recurrence of the condition, to reduce cost, and to prevent the development of antifungal resistance. Lawsone methyl ether, isolated from a plant (Rhinacanthus nasutus leaves) in Thailand, is a cost-effective mouthrinse with potent antifungal activity. Evidence from a carefully designed prospective longitudinal study on a Mexican cohort of HIV/AIDS patients, not receiving anti-retroviral treatment, revealed that the onset of oral candidiasis and oral hairy leukoplakia was heralded by a sustained reduction of CD4+, with an associated sharp increase in viral load. Analysis of the data obtained from a large cohort of HIV/AIDS patients in India could not establish a systemic or local cause of oral melanin pigmentation. A possible explanation was a dysfunctional immune system that increased melanin production. However, longitudinal studies may contribute to a better understanding of this phenomenon. Finally, a development plan was presented that could provide a reliable prediction of disease progression. To be useful in developing countries, the index should be independent of costly blood counts and viral load.
Get full access to this article
View all access options for this article.
References
1.
Barasch A, Safford MM, Dapkute-Marcus I, Fine DH (2004). Efficacy of chlorhexidine gluconate rinse for treatment and prevention of oral candidiasis in HIV-infected children: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod97:204–207.
2.
Begg MD, Panageas KS, Mitchell-Lewis D, Bucklan RS, Phelan JA, Lamster IB (1996). Oral lesions as markers of severe immunosuppression in HIV-infected homosexual men and injection drug users. Oral Surg Oral Med Oral Pathol Oral Radiol Endod82:276–283.
3.
Begg MD, Lamster IB, Panageas KS, Mitchell-Lewis D, Phelan JA, Grbic JT (1997). A prospective study of oral lesions and their predictive value for progression of HIV disease. Oral Dis3:176–183.
4.
Bendick C, Scheifele C, Reichart PA (2002). Oral manifestations in 101 Cambodians with HIV and AIDS. J Oral Pathol Med31:1–4.
5.
Birnbaum W, Hodgson TA, Reichart PA, Sherson W, Nittayannanta SW, Axéll TE (2002). Prognostic significance of HIV-associated oral lesions and their relation to therapy. Oral Dis8(Suppl 2):110–114.
6.
Campo J, Del Romero J, Castilla J, García S, Rodríguez C, Bascones A (2002). Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lymphocyte percentage in HIV-infected patients. J Oral Pathol Med31:5–10.
7.
Carballo E, Aguilera A, Regueiro B, Barrio E (1994). Human immunodeficiency virus type 2 infection in 2 seamen of the northwest of Spain [article in Spanish]. Med Clin (Barc)102:101–103.
8.
Caride E, Hertogs K, Larder B, Dehertogh P, Brindeiro R, Machado E, et al. (2001). Genotyping and phenotyping analysis of B and non-B HIV-1 subtypes from Brazilian patients under HAART (abstract). Antiviral Therapy5(Suppl 3):128.
9.
Centers for Disease Control and Prevention (CDC) (1992). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbid Mortal Wkly Rep41:1–19.
10.
Chattopadhyay A, Gray LR, Patton L, Caplan DJ, Slade GD, Tien HC, et al. (2004). Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type1-infected persons. Infect Immun72:1956–1963.
11.
Chattopadhyay A, Caplan DJ, Slade GD, Shugars DC, Tien HC, Patton LL (2005a). Incidence of oral candidiasis and oral hairy leukoplakia in HIV-infected adults in North Carolina. Oral Surg Oral Med Oral Pathol Oral Radiol Endod99:39–47.
12.
Chattopadhyay A, Caplan DJ, Slade GD, Shugars DC, Tien HC, Patton LL (2005b). Risk indicators for oral candidiasis and oral hairy leukoplakia in HIV-infected adults. Community Dent Oral Epidemiol33:35–44.
13.
Chidzonga MM (2003). HIV/AIDS orofacial lesions in 156 Zimbabwean patients at referral oral and maxillofacial surgical clinics. Oral Dis9:317–322.
14.
Dale BA (2002). Periodontal epithelium: a newly recognized role in health and disease. Periodontol 200030:70–78.
15.
Dawid AAP (2002). Influence diagrams for causal modeling and inference. Stat Rev2:161–189.
16.
EC-Clearinghouse on Oral Problems Related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Human Immunodeficiency Virus (1993). Classification and diagnostic criteria for oral lesions in HIV infection. J Oral Pathol Med22:289–291.
17.
Falqueto J, Lima W, Borges PSS, Barreto JM (2004). The measurement of artificial intelligence-an IQ machine. http://citeseer.ist.psu.edu/592359.html; last accessed April 5, 2006.
18.
Ficarra G, Shillitoe EJ, Adler-Storthz K, Gaglioti D, Di Pietro M, Riccardi R, et al. (1990). Oral melanotic macules in patients infected with human immunodeficiency virus. Oral Surg Oral Med Oral Pathol70:748–755.
19.
Glick M, Muzyka BC, Lurie D, Salkin LM (1994). Oral manifestations associated with HIV-related disease as markers for immune suppression and AIDS. Oral Surg Oral Med Oral Pathol77:344–349.
20.
Gnaore E, Sassan-Morokro M, Kassim S, Ackah A, Yesso G, Adjorlolo G, et al. (1993). A comparison of clinical features in tuberculosis associated with infection with human immunodeficiency viruses 1 and 2. Trans R Soc Trop Med Hyg87:57–59.
21.
Goldstein B, Berman B, Sukenik E, Frankel SJ (1997). Correlation of skin disorders with CD4 lymphocyte counts in patients with HIV/AIDS. J Am Acad Dermatol36(2 Pt 1):262–264.
22.
Greenland S, Brumback B (2002). An overview of relations among causal modelling methods. Int J Epidemiol31:1030–1037.
23.
Greenspan D, Greenspan JS, Heart NG, Pan LZ, Conant MA, Abrams DI, et al. (1987). Relation of oral hairy leukoplakia to infection with the human immunodeficiency virus and the risk of developing AIDS. J Infect Dis155:475–481.
24.
Greenspan D, Komaroff E, Redford M, Phelan JA, Navazesh M, Alves ME, et al. (2000). Oral mucosal lesions and HIV viral load in the Women’s Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr25:44–50.
25.
Greenspan D, Gange SJ, Phelan JA, Navazesh M, Alves ME, MacPhail LA, et al. (2004). Incidence of oral lesions in HIV-1-infected women: reduction with HAART. J Dent Res83:145–150.
26.
Greenspan JS, Greenspan D (2002). The epidemiology of the oral lesions of HIV infection in the developed world. Oral Dis8(Suppl 2):34–39.
27.
Hernan MA, Hernandez-Diaz S, Werler MM, Mitchell AA (2002). Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol155:176–184.
28.
Hilton JF, MacPhail LA, Pascasio L, Sroussi HY, Cheikh B, LaBao ME, et al. (2004). Self-care intervention to reduce oral candidiasis recurrences in HIV-seropositive persons: a pilot study. Community Dent Oral Epidemiol32:190–200.
29.
Holmes HK, Stephen LX (2002). Oral lesions of HIV infection in developing countries. Oral Dis8(Suppl 2):40–43.
30.
Hu DJ, Buve A, Baggs J, van der Groen G, Dondero TJ (1999). What role does HIV-1 subtype play in transmission and pathogenesis? An epidemiological perspective. AIDS13:873–881.
31.
Kloser PC, Mangia AJ, Leonard J, Lombardo JM, Michaels J, Denny TN, et al. (1989). HIV-2-associated AIDS in the United States. The first case. Arch Intern Med149:1875–1877.
32.
Labandeira J, Peteiro C, Toribio J (1994). Hairy leucoplakia and HIV-2-a case report and review of the literature. Clin Exp Dermatol19:335–340.
33.
Langford A, Pohle HD, Gelderblom H, Zhang X, Reichart PA (1989). Oral hyperpigmentation in HIV-infected patients. Oral Surg Oral Med Oral Pathol67:301–307.
34.
Lemey P, Pybus OG, Wang B, Saksena NK, Salemi M, Vandamme AM (2003). Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci USA100:6588–6592.
35.
Lupetti A, Danesi R, van ’t Wout JW, van Dissel JT, Senesi S, Nibbering PH (2002). Antimicrobial peptides: therapeutic potential for the treatment of Candida infections. Expert Opin Investig Drugs11:309–318.
36.
Malkin JE, Prazuck T, Simonnet F, Yameogo M, Rochereau A, Ayeroue J, et al. (1997). Tuberculosis and human immunodeficiency virus infection in west Burkina Faso: clinical presentation and clinical evolution. Int J Tuberc Lung Dis1:68–74.
37.
Margiotta V, Campisi G, Mancuso S, Accurso V, Abbadessa V (1999). HIV infection: oral lesions, CD4+ cell count and viral load in an Italian study population. J Oral Pathol Med28:173–177.
38.
Margiotta V, Campisi G, Mancuso S (2000). Plasma HIV-1 RNA and route of transmission in oral candidiasis and oral hairy leukoplakia. Oral Dis6:194–195.
39.
Masci JR (2000). Complete response of severe, refractory oral candidiasis to mouthwash containing lactoferrin and lysozyme. AIDS14:2403–2404.
40.
Motsei ML, Lindsey KL, van Staden J, Jager AK (2003). Screening of traditionally used South African plants for antifungal activity against Candida albicans. J Ethnopharmacol86:235–241.
41.
Mulligan R, Phelan JA, Brunelle J, Redford M, Pogoda JM, Nelson E, et al. (2004). Baseline characteristics of participants in the oral health component of the Women’s Interagency HIV Study. Community Dent Oral Epidemiol32:86–98.
42.
Ndiaye CF, Critchlow CW, Leggott PJ, Kiviat NB, Ndoye I, Robertson PB, et al. (1997). Periodontal status of HIV-1 and HIV-2 seropositive and HIV seronegative female commercial sex workers in Senegal. J Periodontol68:827–831.
43.
Ndiaye CF, Ba A, Fall AG, Critchlow C (2002). Epidemiology of HIV-1 and HIV-2 associated oral lesions (abstract). Oral Dis8(Suppl 2):177.
44.
Ndour M, Sow PS, Coll-Seck AM, Badiane S, Ndour CT, Diakhate N, et al. (2000). AIDS caused by HIV1 and HIV2 infection: are there clinical differences? Results of AIDS surveillance 1986–97 at Fann Hospital in Dakar, Senegal. Trop Med Int Health5:687–691.
45.
Nicolatou-Galitis O, Velegraki A, Paikos S, Economopoulou P, Stefaniotis T, Papanikolaou IS, et al. (2004). Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. AGreek study. Oral Dis10:145–150.
46.
Nittayananta W, Chungpanich S (1997). Oral lesions in a group of Thai people with AIDS. Oral Dis3(Suppl 1):S41–S45.
47.
Nittayananta W, Nauntofte B, Dabelsteen E, Stolze K, Chanowanna N, Jeales S (2006a). Salivary and oral findings in HIV and HIV-free subjects with a well-controlled consumption of medication (abstract). Adv Dent Res19:168.
48.
Nittayananta W, DeRouen T, Arirachakaran P, Laothumthut T, Pangsomboon K, Petsantad S, et al. (2006b). Chlorhexidine mouth-rinse in maintenance of oral candidiasis-free period among HIV-infected subjects (abstract). Adv Dent Res19:170.
49.
Panichayupakaranant P, Reanmongkol W (2002). Evaluation of chemical stability and skin irritation of Lawsone methyl ether in oral base. Pharm Biol40:429–432.
50.
Panichayupakaranant P, Yuenyongsawad S, Reanmongkol W (2000). Lawsone methyl ether in oral base and its chemical stability. Songklanakarin J Sci Technol22:523–527.
51.
Patton LL (2000). Sensitivity, specificity, and positive predictive value of oral opportunistic infections in adults with HIV/AIDS as markers of immune suppression and viral burden. Oral Surg Oral Med Oral Pathol Oral Radiol Endod90:182–188.
52.
Patton LL, McKaig RG, Eron JJ Jr, Lawrence HP, Strauss RP (1999). Oral hairy leukoplakia and oral candidiasis as predictors of HIV viral load [letter]. AIDS13:2174–2176.
53.
Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ Jr (2000). Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod89:299–304.
54.
Patton LL, Bonito AJ, Shugars DA (2001). A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod92:170–179.
Pillay D, Sinka K, Rice P, Peters B, Clarke J, Workman J, et al. (2000). Impact of HIV-1 subtype on NNRTI resistance mutations (abstract). Antiviral Therapy5(Suppl 3):128.
57.
Porter SR, Luker J, Scully C, Glover S, Griffiths MJ (1989). Orofacial manifestations of a group of British patients infected with HIV-1. J Oral Pathol Med18:47–48.
58.
Porter SR, Glover S, Scully C (1990). Oral hyperpigmentation and adrenocortical hypofunction in a patient with acquired immunodeficiency syndrome. Oral Surg Oral Med Oral Pathol67:59–60.
59.
Powderly WG, Gallant JE, Ghannoum MA, Mayer KH, Navarro EE, Perfect JR (1999). Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. AIDS Res Hum Retroviruses15:1619–1623.
60.
Prasert J, Leewatthanakorn T, Piamsawad U, Dejrudee A, Panichaynpakarananant P, Nittayananta W, et al. (2006). Antifungal activity of potassium Lawsone methyl ether mouthwash in comparison with chlorhexidine mouthwash on oral Candida isolated from HIV/AIDS subjects (abstract). Adv Dent Res19:170.
61.
Ramírez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, Ponce-de-Leon S, Ponce-de-Leon S (1998). Oral manifestations of HIV infection by gender and transmission category in Mexico City. J Oral Pathol Med27:135–140.
62.
Ramírez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, Soto-Ramírez L, González-Ramírez I, Anaya-Saavedra G, et al. (2001). Oral clinical markers and viral load in a prospective cohort of Mexican HIV-infected patients. AIDS15:1910–1911.
63.
Ramírez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, Anaya-Saavedra G, González-Ramírez I, Ponce-de-León S (2003). The changing clinical spectrum of human immunodeficiency virus (HIV)-related oral lesions in 1,000 consecutive patients. A twelve-year study in a referral center in Mexico. Medicine (Baltimore)82:39–50.
64.
Ranganathan K, Reddy BV, Kumarasamy N, Solomon S, Viswanathan R, Johnson NW (2000). Oral lesions and conditions associated with human immunodeficiency virus infection in 300 South Indian patients. Oral Dis6:152–157.
65.
Ranganathan K, Umadevi M, Saraswathi TR, Kumarasamy N, Solomon S, Johnson N (2004). Oral lesions and conditions associated with human immunodeficiency virus infection in 1000 south-Indian patients. Ann Acad Med Sing33(4 Suppl):37–42.
66.
Schiødt M, Bakilana PB, Hiza JF, Shao JF, Bygbjerg IB, Mbaga I, et al. (1990). Oral candidiasis and hairy leukoplakia correlate with HIV infection in Tanzania. Oral Surg Oral Med Oral Pathol69:591–596.
67.
Schmidt-Westhausen AM, Priepke F, Bergmann FJ, Reichart PA (2000). Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. J Oral Pathol Med29:336–341.
68.
Slade GD, editor (1997). Measuring oral health quality of life. Chapel Hill, NC, USA: Dept. of Dental Ecology, School of Dentistry, University of North Carolina.
69.
Smith KJ, Skelton HG, Heimer W, Baxter D, Angritt P, Frisman D, et al. (1993). Melanocytic activation in HIV-1 disease: HMB-45 staining in common acquired nevi [Military Medical Consortium for the Advancement of Retroviral Research]. J Am Acad Dermatol29:539–544.
70.
Smith KJ, Skelton HG, Yeager J, Ledsky R, McCarthy W, Baxter D, et al. (1994). Cutaneous findings in HIV-1 positive patients: a 42 month prospective study [Military Medical Consortium for the Advancement of Retroviral Research]. J Am Acad Dermatol31:746–754.
71.
Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG (2003). Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother51:229–240.
72.
Stebbing J, Moyle G (2003). The clades of HIV: their origins and clinical significance. AIDS Rev5:205–213.
73.
Tadini G, D’Orso M, Cusini M, Alessi E (1991). Oral mucosa pigmentation: a new side effect of azidothymidine therapy in patients with acquired immunodeficiency syndrome. Arch Dermatol127:267–268.
74.
Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, et al. (1994). Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol243:369–387.
75.
Tatt ID, Barlow KL, Nicoll A, Clewley JP (2001). The public health significance of HIV-1 subtypes. AIDS15(Suppl 5):S59–S71.
76.
Vaijayanthimala J, Anandi C, Udhaya V, Pugalendi KV (2000). Anticandidal activity of certain South Indian medicinal plants. Phytother Res14:207–209.
77.
Wainberg MA (2004). HIV-1 subtype distribution and the problem of drug resistance. AIDS18(Suppl 3):S63–S68.
